Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Diagnostic Radiology
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Diagnostic Radiology
    MRI Can Predict Outcome of Infants Deficient of Oxygen at Birth - (DGNews)
    On-Demand versus Routine Radiographs for Ventilated Patients Has Benefits in Clinical Practice - (DGNews)
    Combining Calcium Scoring, SPECT Gives More Accurate Read on Patients' Heart Risk - (DGNews)
    Low-Dose Radiation Angiograms Successful in Diagnosing Congenital Lung Lesions in Neonates: Presented at AAP - (DGDispatch)
    Non-Invasive Diagnostic Tool Can Differentiate Among Small Round Blue Tumours: Presented at AAP - (DGDispatch)

    News archive

     Recent webcasts/CME - Diagnostic Radiology
      Diffusion-Weighted Imaging: Not All That Glitters Is Gold
      The Many Facets of Cardiovascular Magnetic Resonance Imaging: Review of Background, Clinical Utility, and Increasing Use in the Community Hospital
      An Introduction to Pleural Ultrasonography for the Pulmonary and Critical Care Physician
      Intravascular Ultrasound: Insights into Atherosclerosis
      The Future of Cardiac Pacing

      Webcasts/CME archive

       Recent cases - Diagnostic Radiology
        Giant Thoracic Schwannoma Presenting with Abrupt Onset of Abdominal Pain: A Case Report
        Cardiovascular Magnetic Resonance of Myocardial Infarction After Blunt Chest Trauma: A Heartbreaking Soccer-Shot
        Early Lesion of Creutzfeldt-Jakob Disease Detected by Standardizing Diffusion-Weighted Images
        The Mount Fuji Sign on MRI
        Extensive Injuries Following a 'Trip at Home': A Case Report

        Cases archive
          




        my personal edition > diagnostic radiology > news
        divider

          E-Mail this DGNews to a colleague

        DGNews


        Updated Boxed Warning for Micro-Bubble Contrast Agents

          ROCKVILLE, Md -- July 17, 2008 -- The US Food and Drug Administration (FDA) issued an alert to update healthcare professionals about changes that were made to the Boxed Warning, Warnings, and Contraindications sections of the prescribing information for micro-bubble contrast agents in May and June 2008.

          The revised Boxed Warning and Warnings continue to highlight the risk of serious cardiopulmonary reactions during or within 30 minutes following the administration of these products. The revisions recommend that high-risk patients with pulmonary hypertension or unstable cardiopulmonary conditions be closely monitored during and for at least 30 minutes postadministration of these contrast agents.

          Concurrent with these labelling changes, the FDA required that manufacturers of micro-bubble contrast agents conduct clinical studies to more thoroughly assess the risks for serious cardiopulmonary reactions.

          Several of the Contraindications that were added to the labelling in October 2007 were removed because the FDA determined that, in some patients, the benefits from the diagnostic information that could be obtained through the use of perflutren lipid microsphere (Definity) injectable suspension or perflutren protein-type A microspheres for injection (Optison) may outweigh the risk for serious cardiopulmonary reactions, even among some patients at particularly high risk for these reactions.

          The Contraindications that were removed include worsening or clinically unstable congestive heart failure, acute myocardial infarction or acute coronary syndromes, serious ventricular arrhythmias or high risk of arrhythmias due to prolongation of the QT interval, respiratory failure, severe emphysema, and pulmonary emboli or other conditions that cause pulmonary hypertension.

          These changes reflect conclusions of FDA reviews related to information received following the addition of new contraindications and warnings to the labelling for these products in October 2007.


          SOURCE: US Food and Drug Administration




        E-Mail this DGNews to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send